| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Bailey Evan Prescott | Chief Medical Officer | C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK | /s/ Leslie D. Funtleyder, as attorney-in-fact | 03 Feb 2026 | 0002071667 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | APLT | Common Stock | Award | $0 | +437,500 | +51% | $0.000000 | 1,296,816 | 19 Dec 2025 | Direct | F1, F2 |
| transaction | APLT | Common Stock | Disposed to Issuer | -1,235,915 | -95% | 60,901 | 03 Feb 2026 | Direct | F3, F4 | ||
| transaction | APLT | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -60,901 | -100% | 0 | 03 Feb 2026 | Direct | F3, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | APLT | Stock Option (Right to Buy) | Disposed to Issuer | -19,531 | -100% | 0 | 03 Feb 2026 | Common Stock | 19,531 | $1.05 | Direct | F6 | ||
| transaction | APLT | Stock Option (Right to Buy) | Disposed to Issuer | -4,883 | -100% | 0 | 03 Feb 2026 | Common Stock | 4,883 | $1.05 | Direct | F6 |
Evan Prescott Bailey is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in full upon the earlier of (i) the consummation of a Change in Control (as defined in the Plan) or (ii) June 19, 2026, in each case, subject to the Reporting Person continuing to provide services through each such date. |
| F2 | The total holdings have been adjusted to correct an administrative error in prior Form 4s that resulted in the understatement of the total holdings. |
| F3 | Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). |
| F4 | Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration. |
| F5 | Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration. |
| F6 | Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |